EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Unveiling the mechanism of Buddleja officinalis against esophageal squamous cell carcinoma through network pharmacology and molecular docking approaches

Cheng Chang, Zhen Zhen Yang, Yin Sen Song, Na Gao, Hao Zhe Zhang, Xiao Lin Zhang, Tian Li Fan

Tumor Discovery · 2024

DOI: 10.36922/td.2312 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Tumor Discovery, 2024. Verfasst von Cheng Chang und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this research, we aim to explore the underlying mechanism of Buddleja officinalis (BO) in inhibiting esophageal squamous cell carcinoma (ESCC) by means of network pharmacology and molecular docking approaches. First, BO component targets were determined from the Traditional Chinese Medicine Systematic Pharmacology and HERB databases (known as BenCaoZuJian in Chinese transliteration), and ESCC disease targets were identified from GeneCards and DisGeNET databases. Second, the Venny 2.1 online tool was utilized to visualize the intersection targets, and shared potential targets between BO and ESCC were identified using the STRING database. Third, the component-target-pathway networks were constructed using Cytoscape software. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes were utilized for further analyzing the mechanism of BO in inhibiting ESCC. Finally, molecular docking technique was employed to delineate the docking profiles of BO and determine the optimal active component, which is threonine protein kinase (AKT1). We screened six active components and 227 targets from BO, of which 24 were shared targets of ESCC and BO. The network pharmacology analysis indicated core targets with high degrees, namely, serum albumin, insulin-like growth factor 1 receptor, AKT1, estrogen receptor, and basic fibroblast growth factor receptor 1, which are the most likely binding sites for the active components in BO. The related signaling pathways underpinning the inhibition of ESCC by BO encompass MAPK signaling pathway, adhesion junction pathway, and gastric cancer pathway. Moreover, linarin was recognized as the most suitable component for AKT1. Our results revealed that BO exhibits multicomponent, multi-target, and multi-pathway characteristics, which offer a scientific foundation for elucidating its therapeutic mechanism in ESCC and present novel insights for future investigations.

Zitieren

APA

Chang, C., Yang, Z. Z., Song, Y. S., Gao, N., Zhang, H. Z., Zhang, X. L., & Fan, T. L. (2024). Unveiling the mechanism of Buddleja officinalis against esophageal squamous cell carcinoma through network pharmacology and molecular docking approaches. Tumor Discovery. https://doi.org/10.36922/td.2312

Vancouver

Chang C, Yang ZZ, Song YS, Gao N, Zhang HZ, Zhang XL, et al. Unveiling the mechanism of Buddleja officinalis against esophageal squamous cell carcinoma through network pharmacology and molecular docking approaches. Tumor Discovery. 2024. doi:10.36922/td.2312

BibTeX
@article{Chang2024,
  author = {Chang, Cheng and Yang, Zhen Zhen and Song, Yin Sen and Gao, Na and Zhang, Hao Zhe and Zhang, Xiao Lin and Fan, Tian Li},
  title = {Unveiling the mechanism of Buddleja officinalis against esophageal squamous cell carcinoma through network pharmacology and molecular docking approaches},
  journal = {Tumor Discovery},
  year = {2024},
  doi = {10.36922/td.2312}
}
Kostenlos starten →